Feb 25, 2025 Yale researchers recognise post-vaccination syndrome (PVS)

Press release from Yale, Feb 19, 2025 https://news.yale.edu/2025/02/19/immune-markers-post-vaccination-syndrome-indicate-future-research-directions

Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination

https://www.medrxiv.org/content/10.1101/2025.02.18.25322379v1

Chronic symptoms that developed a day or two soon after receiving a COVID-19 vaccine,

can become more severe in the days that follow,

PVS, little-understood, persistent condition,

remains unrecognized by medical authorities.

Common chronic symptoms of PVS

Excessive fatigue (85%)

Tingling and numbness (80%)

Exercise intolerance (80%)

Brain fog (77.5%)

Difficulty concentrating or focusing (72.5%)

Trouble falling or staying asleep (70%)

Neuropathy (70%)

Muscle aches (70%)

Anxiety (65%)

Tinnitus (60%)

Burning sensations (57.5%).

Getting out of breath Palpitations Headache Dizziness Lower quality of life scores

Mechanisms

Vaccine-induced immune responses may be triggering the stimulation of autoreactive lymphocytes.

Unregulated stimulation of innate immunity could lead to chronic inflammation.

Participants with PVS have a distinct set of autoantibodies.

A subset of non-classical monocytes has been shown to harbor S protein in patients with PVS

Biodistribution studies on mRNA–LNP platforms in indicate its ability to cross the blood-brain barrier,

and the local S expression could result in neurocognitive symptoms.

Compared with controls

PVS had reduced circulating memory and effector CD4 T cells,

and an increase in TNFα+ CD8 T cells.

Serological evidence of recent Epstein-Barr virus (EBV) reactivation, more frequent in PVS.

Measured levels of SARS-CoV-2 spike protein

Participants with PVS had significantly higher circulating S1 levels compared with the control group (p = 0.01).

PVS, (even those without evidence for infection), higher levels of spike protein than controls.

Detectable S1 was found in participants’ plasma ranging from 26 to 709 days from the most recent known vaccination.

“That was surprising, to find spike protein in circulation at such a late time point,”

(Some PVS patients didn’t have any measurable spike protein).

Autoimmunity, tissue damage, Epstein-Barr Virus (EBV) reactivation, (infectious mononucleosis)

https://www.medrxiv.org/content/Immun… and Antigenic Signatures Associated with Chronic Illnesses after1 COVID-19 Vaccination.pdf

Yale LISTEN study.

LISTEN stands for Listen to Immune, Symptom and Treatment Experiences Now.

https://medicine.yale.edu/ycci/listen…

42 LISTEN PVS patients (some never infected)

22 who did not report any PVS symptoms after COVID-19 vaccination.

“It’s clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help,”